Last reviewed · How we verify
TAK-020 Captisol Oral Solution — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
TAK-020 Captisol Oral Solution (TAK-020 Captisol Oral Solution) — Takeda.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| TAK-020 Captisol Oral Solution TARGET | TAK-020 Captisol Oral Solution | Takeda | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- TAK-020 Captisol Oral Solution CI watch — RSS
- TAK-020 Captisol Oral Solution CI watch — Atom
- TAK-020 Captisol Oral Solution CI watch — JSON
- TAK-020 Captisol Oral Solution alone — RSS
Cite this brief
Drug Landscape (2026). TAK-020 Captisol Oral Solution — Competitive Intelligence Brief. https://druglandscape.com/ci/tak-020-captisol-oral-solution. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing